Allogene Therapeutics, Inc. (ALLO) — SEC Financial Statements & Analysis

Allogene Therapeutics, Inc. (ALLO) is a biological products, (no diagnostic substances) company. Allogene Therapeutics, Inc. trades on Nasdaq as: ALLO. Allogene Therapeutics, Inc. (ALLO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, Allogene Therapeutics, Inc. carries a market cap of $684.17M, a P/E ratio of -4.13x, a P/B ratio of 1.57x, a P/S ratio of 147.45x, an enterprise value of $635.26M, and an EV/EBITDA multiple of -3.77x. On profitability, it posts an operating margin of -3886.14%, a net margin of -3566.68%, a Return on Equity (ROE) of -42.39%, a Return on Assets (ROA) of -32.43%, and a Return on Invested Capital (ROIC) of -53.88%. Per share, it reports EPS of $-0.50, diluted EPS of $-0.50, free cash flow per share of $-0.31, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -30.14% year-over-year, and EPS growth of -53.51% year-over-year. On the balance sheet, it maintains a current ratio of 10.72x, a quick ratio of 10.48x, working capital of $308.27M, a debt-to-equity ratio of 0.26x, a debt ratio of 0.21, an interest coverage ratio of -138.71x, free cash flow of $-102.60M (TTM), and net debt of $-48.92M. Figures sourced from SEC EDGAR.

Market Cap

$684.17M

P/E TTM

-4.13x

EPS TTM

$-0.50

P/B TTM

1.57x

ROE TTM

-42.39%

ROA TTM

-32.43%

Debt To Equity

0.26x

Free Cash Flow TTM

$-102.60M

Net Revenue TTM Growth 1Y

-100.00%

Data as of 2026-06-30 · Source: SEC EDGAR